Abstract: The invention enables direct oral granules enabling controlled release of magnesium, having both extended-release and non-extended-release fractions. The granules include extended-release particles having a magnesium-containing core and a lipophilic coating, with at least the cores of these extended-release particles having a mandated abrasion resistance which is determined by means of vibration screening over a period of 60 minutes and which allows these cores to be melt-coated, more particularly melt-coated with lipids in a fluidized bed. The invention further provides a method for characterizing the magnesium-containing cores, and also a process for producing the extended-release particles by means of hotmelt coating.

Abstract: The invention provides a method for the preparation of effervescent granules wherein the reactive, effervescent components (one acidic and one alkaline CO2-generating component) are brought to reaction with one another under stirring in a vacuum (100-900 mbar) in an evacuable mixing chamber, with said mixing chamber being evacuated to a first vacuum value p1, and then ‘re-evacuated’ to said first vacuum value p1 again, optionally repeatedly, once the pressure has increased to a second vacuum value p2 due to the progressing CO2 formation of the effervescent reaction. The method is carried out in such a way that during at least the effervescent reaction step(s) the stirring speed in the mixing chamber exhibits a Froude number (Fr) of 0.5 or higher, preferably 0.8 or higher, more preferably 0.9 or higher; such as, in the range of 0.50 to 8.00, or 0.80 to 8.00, or 0.90 to 8.00.

Abstract: The present invention relates to a method of producing a pharmaceutical preparation that contains a proton pump inhibitor and optionally a non-steroidal anti-inflammatory drug in the form of pellets. The invention further relates to pharmaceutical preparations obtainable by said method, in particular those with a defined dissolution profile.

Abstract: The invention relates to a stable medicament for oral administration which comprises (a) a core which contains an active ingredient selected from Omeprazole, Lansoprazole and Pantoprazole, together with customary pharmaceutical adjuvants, (b) an intermediate layer applied onto the core, and (c) a gastric juice-resistant outer layer. The intermediate layer in (b) is formed as a reactive layer in which a gastric juice-resistant polymer layer material partially neutralized with alkali with cation exchange capacity is present. Further, a method for the production of the stable medicament is disclosed.

Abstract: The invention relates to a stable medicament for oral administration which comprises (a) a core which contains an active ingredient selected from Omeprazole, Lansoprazole and Pantoprazole, together with customary pharmaceutical adjuvants, (b) an intermediate layer applied onto the core, and (c) a gastric juice-resistant outer layer. The intermediate layer in (b) is formed as a reactive layer in which a gastric juice-resistant polymer layer material partially neutralized with alkali with cation exchange capacity is present. Further, a method for the production of the stable medicament is disclosed.

Abstract: The invention relates to a stable medicament for oral administration which comprises (a) a core which contains an active ingredient selected from Omeprazole, Lansoprazole and Pantoprazole, together with customary pharmaceutical adjuvants, (b) an intermediate layer applied onto the core, and (c) a gastric juice-resistant outer layer. The intermediate layer in (b) is formed as a reactive layer in which a gastric juice-resistant polymer layer material partially neutralized with alkali with cation exchange capacity is present. Further, a method for the production of the stable medicament is disclosed.

Abstract: The invention relates to a stable medicament for oral administration which comprises (a) a core which contains an active ingredient selected from Omeprazole, Lansoprazole and Pantoprazole, together with customary pharmaceutical adjuvants, (b) an intermediate layer applied onto the core, and (c) a gastric juice-resistant outer layer. The intermediate layer in (b) is formed as a reactive layer in which a gastric juice-resistant polymer layer material partially neutralized with alkali with cation exchange capacity is present. Further, a method for the production of the stable medicament is disclosed.

Abstract: The invention relates to a stable medicament for oral administration which comprises